Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
Eisai’s strategy focusing on neurology and oncology set in its midterm business plan, dubbed “EWAY 2025” kicked off in April, “is gradually producing results,” stressed CEO Haruo Naito at an earnings briefing on October 31. “Particularly, we see steady progress…
To read the full story
Related Article
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
November 1, 2016
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
October 13, 2016
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…